WallStreetZenWallStreetZen

NASDAQ: IPA
Immunoprecise Antibodies Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for IPA

Based on 2 analysts offering 12 month price targets for Immunoprecise Antibodies Ltd

Min Forecast
$3.00+506.06%
Avg Forecast
$4.00+708.08%
Max Forecast
$5.00+910.1%

Should I buy or sell IPA stock?

Based on 2 analysts offering ratings for Immunoprecise Antibodies Ltd.

Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their IPA stock forecasts and price targets.

IPA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-11
lockedlocked$00.00+00.00%2025-04-01

1 of 1

Forecast return on equity

Is IPA forecast to generate an efficient return?

Company
15.06%
Industry
147.51%
Market
89.83%
IPA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IPA forecast to generate an efficient return on assets?

Company
8.31%
Industry
39.49%
IPA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IPA earnings per share forecast

What is IPA's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.08
Avg 2 year Forecast
$0.01
Avg 3 year Forecast
$0.08

IPA revenue forecast

What is IPA's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$20.2M+21.09%
Avg 2 year Forecast
$26.7M+59.97%
Avg 3 year Forecast
$30.8M+84.64%
IPA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

IPA revenue growth forecast

How is IPA forecast to perform vs Biotechnology companies and vs the US market?

Company
23.2%
Industry
58.5%
Market
9.77%
IPA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
IPA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

IPA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IPA$0.50$4.00+708.08%Buy
NRXS$2.25N/AN/A
CING$3.82$30.67+702.80%Strong Buy
GLYC$0.25N/AN/A
LPTX$0.40$5.50+1,271.57%Buy
View Top Biotech Stocks

Immunoprecise Antibodies Stock Forecast FAQ

Is Immunoprecise Antibodies Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: IPA) stock is to Buy IPA stock.

Out of 2 analysts, 0 (0%) are recommending IPA as a Strong Buy, 2 (100%) are recommending IPA as a Buy, 0 (0%) are recommending IPA as a Hold, 0 (0%) are recommending IPA as a Sell, and 0 (0%) are recommending IPA as a Strong Sell.

If you're new to stock investing, here's how to buy Immunoprecise Antibodies stock.

What is IPA's earnings growth forecast for 2026-2028?

(NASDAQ: IPA) Immunoprecise Antibodies's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.59%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.49%.

Immunoprecise Antibodies's earnings in 2025 is -$32,026,388.On average, 1 Wall Street analyst forecast IPA's earnings for 2026 to be -$2,628,099, with the lowest IPA earnings forecast at -$2,628,099, and the highest IPA earnings forecast at -$2,628,099. On average, 1 Wall Street analyst forecast IPA's earnings for 2027 to be $328,512, with the lowest IPA earnings forecast at $328,512, and the highest IPA earnings forecast at $328,512.

In 2028, IPA is forecast to generate $2,628,099 in earnings, with the lowest earnings forecast at $2,628,099 and the highest earnings forecast at $2,628,099.

What is IPA's revenue growth forecast for 2026-2028?

(NASDAQ: IPA) Immunoprecise Antibodies's forecast annual revenue growth rate of 23.2% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.5%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.77%.

Immunoprecise Antibodies's revenue in 2025 is $16,665,277.On average, 1 Wall Street analysts forecast IPA's revenue for 2026 to be $662,937,882, with the lowest IPA revenue forecast at $662,937,882, and the highest IPA revenue forecast at $662,937,882. On average, 1 Wall Street analysts forecast IPA's revenue for 2027 to be $875,813,872, with the lowest IPA revenue forecast at $875,813,872, and the highest IPA revenue forecast at $875,813,872.

In 2028, IPA is forecast to generate $1,010,832,439 in revenue, with the lowest revenue forecast at $1,010,832,439 and the highest revenue forecast at $1,010,832,439.

What is IPA's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: IPA) forecast ROA is 8.31%, which is lower than the forecast US Biotechnology industry average of 39.49%.

What is IPA's Price Target?

According to 2 Wall Street analysts that have issued a 1 year IPA price target, the average IPA price target is $4.00, with the highest IPA stock price forecast at $5.00 and the lowest IPA stock price forecast at $3.00.

On average, Wall Street analysts predict that Immunoprecise Antibodies's share price could reach $4.00 by Apr 11, 2026. The average Immunoprecise Antibodies stock price prediction forecasts a potential upside of 708.08% from the current IPA share price of $0.50.

What is IPA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: IPA) Immunoprecise Antibodies's current Earnings Per Share (EPS) is -$1.11. On average, analysts forecast that IPA's EPS will be -$0.08 for 2026, with the lowest EPS forecast at -$0.08, and the highest EPS forecast at -$0.08. On average, analysts forecast that IPA's EPS will be $0.01 for 2027, with the lowest EPS forecast at $0.01, and the highest EPS forecast at $0.01. In 2028, IPA's EPS is forecast to hit $0.08 (min: $0.08, max: $0.08).

What is IPA's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: IPA) forecast ROE is 15.06%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.